N@N

Derma Sciences Announces Issuance of Second U.S. Patent Related to MEDIHONEY Alginate Dressing

^{Published on 2010-06-22 04:36:33 - Market Wire}
 

PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to the Companya™s MEDIHONEY^® Calcium Alginate Dressing.

"This newly issued patent, along with others issued and filed, increases the barriers to entry for any meaningful competition within the honey wound and burn care space. Together with our strong brand identity and first-to-market status, we are confident in our market position"

This is the second patent granted in the U.S. covering Derma Sciencesa™ line of proprietary honey-based wound dressings. This new patent further strengthens the intellectual property on the MEDIHONEY® line of dressings, especially with regard to the single-use sterile pouched dressings that are most commonly used in the treatment of wounds and burns.

Derma Sciences Chairman and Chief Executive Officer Edward J. Quilty stated, aAlginate is an ideal delivery mechanism for MEDIHONEY^® because it allows this medical-grade honey to reside on the wound site for an extended period of time. Alginates are known for their significant absorption capacity, and can be removed easily from the wound bed without disrupting the healing process.

aThis newly issued patent, along with others issued and filed, increases the barriers to entry for any meaningful competition within the honey wound and burn care space. Together with our strong brand identity and first-to-market status, we are confident in our market position,a Mr. Quilty added.

MEDIHONEY^®, the leading global brand of honey-based wound care, is a line of wound and burn dressings containing Active Manuka (Leptospermum) Honey from New Zealand. This unique species of medical-grade honey has been shown in several large-scale, randomized controlled clinical studies to possess unique qualities that help to initiate healing in stalled wounds, and assist with fast debridement of non-viable tissue.

MEDIHONEY^® dressings are indicated for the management of leg ulcers, diabetic foot ulcers and pressure ulcers, first and second-degree burns, and traumatic and surgical wounds. MEDIHONEY® alginate dressings have proven to be the most popular of all the MEDIHONEY® dressings in the U.S. as alginates help to keep large quantities of honey at the wound site, while still absorbing up to 18 times the alginatea™s weight in wound fluid.

Alginate dressings are one of the most commonly used dressings within the global $1 billion moist wound dressing market. They are highly absorbent, biodegradable wound care products derived from seaweed and have been proven to be highly effective in managing a wide array of exuding wounds. Their ability to form hydrophilic gel helps contain wound secretions and reduces bacterial contamination. They are preferred dressings for a large percentage of chronic wounds that are partial-to-full thickness in depth with moderate-to-heavy amounts of wound exudates.

About Derma Sciences, Inc.

Derma Sciences is a global medical device and pharmaceutical company focused on wound care. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 leg ulcer patients. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudates, and BIOGUARDa" for infection prevention. Derma Sciences also expects to complete preclinical studies with DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction, by the end of 2010. For more information please visit [ www.dermasciences.com ].

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's fillings with the U.S. Securities and Exchange Commission.